Broncus Holding Company (BHC), announced that it has acquired the assets of privately held Uptake Medical Corp, the manufacturer of vapor technology for the bronchoscopic ablation of emphysema and lung cancer.
Vapor ablation has been shown to result in clinically meaningful improvement in lung function and quality of life in a recent randomized controlled trial published in the Lancet RM (July 2016). The acquisition positions BHC as the leader in providing the complete solution for the two most devastating lung diseases.
BHC's Chairman Michael Zhao explains: "Our plan is to deliver a solution through combination of the technologies from our two companies, Broncus Medical Inc. and Uptake Medical Technology Inc. Broncus Medical Inc. will focus on the complete treatment for Lung cancer and Uptake MedicalTtechnology will focus on the complete treatment for emphysema. Together these two companies represent complete answers for the number one and two leading causes of pulmonary disease."
"We are very excited to be able to offer an impeccable solution to bronchoscopic-based lung cancer treatment through the integration of Uptake's vapor technology and our products, LungPoint and Archimedes", said Henky Wibowo, President of, Broncus Medical Inc., San Jose, CA.
"We are elated to have the additional resources and infrastructures that Broncus provides to rapidly extend our commercialization coverage in the EU and Asia. Additionally, Broncus' products will complement and extend the InterVapor system and further simplify the procedure for treating emphysema patients." said Robert Barry, President of Uptake Medical Technology, Seattle, WA.